Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 9/20 | 0.70 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.70 |
| ▸ | GBA1 | P04062 | 11/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16847391 | 0.86 | HCRTR1 (0.69) | HCRTR1HCRTR2GBA1 | |
| SCHEMBL1671264 | 0.82 | HCRTR2 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL24016912 | 0.80 | HCRTR2 (0.54) | HCRTR1HCRTR2 | |
| SCHEMBL24522228 | 0.80 | HCRTR2 (0.54) | HCRTR1HCRTR2 | |
| SCHEMBL16847398 | 0.78 | HCRTR2 (0.74) | HCRTR1HCRTR2 | |
| SCHEMBL17793737 | 0.78 | HCRTR2 (0.73) | HCRTR1HCRTR2 | |
| SCHEMBL20435434 | 0.78 | HCRTR1 (0.53) | HCRTR1HCRTR2 | |
| SCHEMBL20435456 | 0.77 | HCRTR1 (0.63) | HCRTR1HCRTR2 | |
| SCHEMBL18186735 | 0.77 | GBA1 (0.64) | HCRTR1HCRTR2GBA1 | |
| SCHEMBL5791691 | 0.77 | HCRTR2 (0.57) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732077-B2 | Diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | claimed |
| US-20160318923-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | claimed |
| WO-2015095111-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | claimed |
| US-9732077-B2 | Diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732077-B2 | Diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732077-B2 | Diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160318923-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318923-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318923-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| WO-2015095111-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318923-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR1 | HCRTR1 2/4885HCRTR2 1/4885GBA1 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.